By Connor Hart
PTC Therapeutics will scrap development of its treatment for amyotrophic lateral sclerosis after it failed to meet a primary endpoint in a Phase 2 trial.
The Warren, N.J., biopharmaceutical company said Tuesday that the treatment, called utreloxastat, didn't meet the goal of slowing disease progression, despite having demonstrated to be safe and well tolerated.
"We are of course disappointed that we were not able to demonstrate treatment efficacy and provide a potential therapy that could address the significant unmet medical need of ALS patients," Chief Executive Matthew Klein said.
Shares fell 2.7%, to $44.75, in post-market trading after ending the regular session 7% higher, at $46.01.
ALS, sometimes referred to as Lou Gehrig's disease, is a rare, progressive and fatal neurodegenerative disease that affects motor neurons in the brain and spinal cord.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 26, 2024 17:06 ET (22:06 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。